Basic Stugeron Information

• International Nonproprietary Name (INN): Cinnarizine
• Brand names available in United Kingdom: Stugeron
• ATC Code: N07CA02
• Forms & dosages: 25 mg oral tablet
• Manufacturers in United Kingdom: Janssen Pharmaceuticals, STADA
• Registration status in United Kingdom: Registered
• OTC / Rx classification: OTC for motion sickness

Latest Research Highlights

Recent clinical studies across the UK and EU have delved into the efficacy and safety of Stugeron, the brand name for cinnarizine. These studies primarily focus on indications such as motion sickness and vestibular disorders. Research findings from investigations conducted between 2022 and 2025 highlight a remarkable success rate of up to 80% for patients using Stugeron for motion sickness prevention, especially when taken two hours prior to travel. Safety analyses indicate some common side effects, notably drowsiness. However, they also emphasise a favourable risk-benefit profile in comparison to alternatives such as betahistine and various antihistamines. Data reflecting patient-reported outcomes on NHS platforms reveal significant improvements in quality of life. Many users report experiencing fewer vertigo episodes and enhanced mobility, which validates existing NHS treatment guidelines that endorse Stugeron's efficacy in managing vestibular conditions.

Clinical Outcomes and Safety Data

To provide a clearer perspective on the research findings, below is a summary table encapsulating key clinical outcomes and safety data:

Efficacy Rates	Common Side Effects	Comparative Studies
Success Rate: Up to 80%	Drowsiness, dry mouth, nausea	Favourable vs. betahistine and antihistamines

It is essential that further research focuses on tailored therapeutic approaches and investigates the potential long-term effects of using Stugeron. Ongoing studies are likely to provide more insightful data regarding its use and effectiveness across various patient populations.

Composition & Brand Landscape

Stugeron, known generically as cinnarizine, is a staple in European pharmacies, especially in the UK. This medication plays a crucial role as a calcium channel blocker under the ATC code N07CA02, aimed particularly at handling disorders related to the nervous system.

In the UK market, Stugeron is primarily available as a 25 mg oral tablet. These tablets come in diverse packaging options, catering to patient convenience. Major pharmacy chains such as Boots, Superdrug, and LloydsPharmacy stock it, offering blister packs containing 15, 30, or 50 tablets. Such flexibility supports various patient needs, making access easier.

Beyond the UK, various generics like Cinnarizin Stada and Cinarizina flourish in European markets, ensuring a broader supply of motion sickness solutions. This accessibility highlights the importance of providing treatments for motion sickness through established healthcare channels.

Clinical guidelines position Stugeron as a go-to first-line treatment. Increasingly, online pharmacies are opening up access to this medication, mirroring the escalating trend towards digital healthcare solutions.

Data Highlight: Variations in pricing and availability illustrate differing prescription costs across regions like England, Scotland, Wales, and Northern Ireland.

LSI/NLP Keywords: brand names, dosage forms, pharmaceutical distribution, generics, pharmacy access.

Keyword Cluster: Stugeron brand, pharmaceuticals in the UK, access to medications.

Contraindications & Special Precautions

While Stugeron (cinnarizine) boasts a notable safety profile, it's crucial to be aware of both absolute and relative contraindications.

• Those with known allergies to cinnarizine or any excipients must steer clear of this medication.
• Patients dealing with severe hepatic impairment or porphyria should also avoid Stugeron unless closely monitored by a healthcare professional.
• Pregnant or breastfeeding women are advised against its use unless there's no alternative, warranting tight medical supervision.
• Special caution is necessary for elderly patients and individuals with Parkinson's disease, as the drug could exacerbate symptoms due to its sedative qualities.
• Close monitoring is recommended for patients with liver or kidney issues, as adjustments in dosage might be necessary, given that metabolism occurs primarily through the liver.

In the UK, cultural attitudes to medication push for transparent discussions between pharmacists and patients. Prescribing practices routinely depend on thorough patient assessments to ensure safer therapeutic outcomes.

LSI/NLP Keywords: contraindications, special precautions, patient safety, hepatic impairment, monitoring practices.

Keyword Cluster: patient safety concerns, prescribing guidelines, medication contraindications.

Dosage Guidelines

Cinnarizine is generally prescribed at a standard 25 mg dose for motion sickness. It's effective when taken at least two hours before travel, allowing for a repeat every eight hours as required. In the case of vertigo or vestibular disorders, the typical recommendation is to take 25 mg three times a day, with a ceiling of 75 mg per day.

For children aged 5 to 12, a recommended dose is 12.5 mg two to three times daily, while Stugeron isn't advisable for those under five years.

As for elderly patients, a lowered dose may be necessary to minimise risks such as increased sedation or confusion, common side effects in this demographic.

It's advisable for those with hepatic or renal impairments to seek medical consultation before beginning treatment, as dosage adjustments may be warranted.

Integrating clear dosage guidelines into pharmacy practice ensures proper patient adherence and positively influences treatment outcomes and satisfaction.

LSI/NLP Keywords: dosage guidelines, treatment regimens, patient adherence, age-specific recommendations.

Keyword Cluster: dosing strategies, treatment adherence, patient management practices.

Interactions Overview

Understanding drug interactions is vital when prescribing Stugeron (cinnarizine). Patients should be aware of potential interactions with food and beverage intake.

For example, alcohol can exacerbate the sedative effects of Stugeron, increasing the risk of drowsiness, which may impair activities like driving.

Research using data from the MHRA Yellow Card system highlights that the concurrent use of Stugeron with central nervous system (CNS) depressants—including certain antihistamines, opioids, and sedatives—should be approached with caution. The risk of compounded sedative effects necessitates prudent clinical judgement.

While stimulants like caffeine do not directly interact with cinnarizine, healthcare practitioners often advise patients to limit their intake, especially if they experience sleep disturbances or heightened anxiety.

Pharmacists serve as a crucial resource in the UK healthcare system, advising patients on potential interactions and reinforcing the importance of consulting professionals for medication information.

Data Highlight: Continuous monitoring of interactions and staying updated through MHRA resources is essential for ongoing safety and efficacy.

Cultural Perceptions & Patient Habits

Patient behaviour in the UK regarding Stugeron (cinnarizine) reflects a strong cultural reliance on pharmacist counselling. Many patients turn to community pharmacies, like Boots and Superdrug, seeking advice for motion sickness and vertigo management, underscoring the crucial role pharmacists play in patient education and medication stewardship.

Online forums such as Patient.info and Mumsnet provide insights into public attitudes, revealing a high level of trust in pharmacists for advice on non-prescription medications. Numerous patients share experiences of seeking guidance on managing side effects and clarifying dosing regimens, indicating a proactive approach to health management.

Additionally, NHS 111 serves as a key resource, offering patients immediate access to guidance on the safe use of medications like Stugeron. The cultural context in the UK fosters an environment where patients feel empowered to engage openly with healthcare providers, ultimately improving adherence to treatment guidelines.

As telemedicine grows, digital platforms enhance engagement between patients and healthcare professionals, facilitating seamless conversations about medication management, including Stugeron.

Availability & Pricing Patterns

Stugeron (cinnarizine) is widely accessible across the UK, with many pharmacies, including major chains like Boots, Superdrug, and LloydsPharmacy, providing the medication over-the-counter. This ease of access aligns with NHS guidelines recommending Stugeron as a first-line treatment for motion sickness and related vestibular disorders.

Pricing does vary across different regions, with private purchases generally cheaper in England compared to Scotland, Wales, and Northern Ireland, where NHS prescription practices impact consumer costs. For instance, a private purchase of Stugeron may reach £6.00 per package, whereas an NHS prescription might cost £9.35 in England, with variations elsewhere.

Recent trends show an increase in online pharmacies offering Stugeron, making it even more accessible for individuals who may struggle to visit physical locations. These platforms operate within the regulations set by the MHRA, ensuring a safer purchasing experience.

Data Highlight: Comparative price tables showcasing private versus NHS prescription costs and availability across regions could assist patients in navigating their options.

Comparable Medicines and Preferences

Stugeron (cinnarizine) faces competition from other over-the-counter medicines available for motion sickness and vestibular issues. Alternatives such as Dimenhydrinate (Dramamine) and Meclizine (Antivert) offer similar efficacy but vary in their side effect profiles. Evidence suggests that although Stugeron is frequently preferred due to its historical efficacy, some patients choose alternatives for the milder sedation effects associated with Meclizine.

Betahistine is another alternative, particularly indicated for Ménière’s disease, although it generally requires a prescription, contrasting with the easy accessibility of Stugeron. Unique patient needs often influence medication choices, with Stugeron recognised for its proven effectiveness in the UK market.

As patients navigate their options, providing pros and cons checklists can help evaluate different medications based on effectiveness, side effects, and personal lifestyle factors.

Pharmacies, including Boots and LloydsPharmacy, often highlight these alternatives during consultations, ensuring patients understand their options and enhancing comprehension of available therapies.

FAQ Section

1. What is Stugeron used for?
Stugeron (cinnarizine) is mainly used for motion sickness, vertigo, and certain circulatory disorders.

2. How should I take Stugeron?
The standard adult dosage is 25 mg taken two hours before travel, with the option to repeat every eight hours if necessary.

3. Who should not take Stugeron?
Individuals with known allergies to cinnarizine, severe liver impairment, or specific conditions (e.g., pregnancy) should avoid its use.

4. Can I drive after taking Stugeron?
Due to the potential for drowsiness, patients should exercise caution when driving or operating heavy machinery after dosage.

5. Where can I buy Stugeron?
Stugeron is available over-the-counter at most pharmacies and through various online platforms.

Data Highlight: Referring patients to NHS portals can further enhance their understanding regarding medication use, side effects, and available pharmacy services.

Guidelines for Proper Use

The correct usage of Stugeron (cinnarizine) is critical for ensuring optimal therapeutic outcomes. Patients should receive comprehensive counselling from pharmacists upon purchasing the medication, which should cover dosing instructions and potential side effects.

For motion sickness, it's suggested that patients take 25 mg approximately two hours before travelling, with a possibility of repeating the dose after eight hours if needed. For chronic conditions, regular consultations with healthcare providers are essential to determine appropriate long-term regimens.

Moreover, patients should be advised about the potential interactions with alcohol and specific medications, emphasising the importance of discussing all ongoing treatments with a pharmacist or doctor. Those experiencing excessive drowsiness or side effects should also be prompted to seek medical advice.

Utilising NHS patient portals provides valuable resources, such as dosage guidelines and interactive tools to track symptoms and medication adherence, significantly enhancing the patient experience.

Pharmacists play a vital role in ensuring compliance with guidelines, acting as the first point of contact for patients seeking advice on Stugeron and other medications.

City	Region	Delivery Time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	North West	5–7 days
Glasgow	Scotland	5–9 days
Bristol	South West	5–7 days
Newcastle	North East	5–9 days
Sheffield	South Yorkshire	5–7 days
Leeds	West Yorkshire	5–7 days
Cardiff	Wales	5–9 days
Nottingham	East Midlands	5–7 days
Oxford	South East	5–7 days
Coventry	West Midlands	5–9 days